Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares for the month of June 2025. The filing details a share repurchase executed on June 13, 2025, pursuant to a non-discretionary agreement with Merrill Lynch International entered into on June 4, 2025.
Key Financial Metrics and Transaction Details
- Shares Purchased (June 13, 2025): 356,703 ordinary shares.
- Price Range: Lowest price paid was 1,509.00 GBp; highest price paid was 1,553.00 GBp.
- Volume-Weighted Average Price (VWAP): 1,529.37 GBp.
- Cumulative Purchases (Since June 4, 2025): 2,810,978 ordinary shares.
- Treasury Shares Held: 220,945,361 ordinary shares.
- Shares in Issue (Excluding Treasury): 4,094,356,228 ordinary shares.
- Voting Rights in Treasury: 5.40% of total voting rights.
Material Changes
The filing does not report material changes to revenue, profit, cash flow, margins, or debt. The primary change reported is the reduction of shares in issue and the increase in treasury shares resulting from the buyback program. The total number of voting rights remains 4,094,356,228, which serves as the denominator for shareholder notification calculations under FCA Disclosure Guidance and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no new financial guidance or management commentary regarding operational outlook. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in the "Risk Factors" section of GSK's 2024 Annual Report on Form 20-F and its Q1 2025 Results.
Investor Verification Checklist
- Verify the total cost of the buyback program by multiplying the cumulative shares purchased (2,810,978) by the average price paid.
- Confirm the impact of the 5.40% treasury share holding on earnings per share (EPS) calculations.
- Review the "Risk Factors" in the 2024 Form 20-F and Q1 2025 Results for context on the forward-looking statements mentioned.
- Check the remaining authorization limit for the buyback program, as the filing does not specify the total program size or remaining capacity.